Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31320075 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10PTPN2PTPN1PTPN6 | |
| SCHEMBL23487150 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10PTPN2PTPN1PTPN6 | |
| SCHEMBL23695128 | 0.84 | HSD17B10 (0.41) | SMN1; SMN2HSD17B10PTPN2PTPN1PTPN6 | |
| SCHEMBL23695127 | 0.84 | HSD17B10 (0.41) | SMN1; SMN2HSD17B10PTPN2PTPN1PTPN6 | |
| SCHEMBL24047701 | 0.84 | HSD17B10 (0.50) | SMN1; SMN2HSD17B10HPGDRECQL | |
| SCHEMBL1439128 | 0.84 | HSD17B10 (0.50) | SMN1; SMN2HSD17B10HPGDRECQL | |
| SCHEMBL26430589 | 0.84 | HSD17B10 (0.50) | SMN1; SMN2HSD17B10HPGDRECQL | |
| SCHEMBL21748842 | 0.80 | CHRM2 (0.39) | SMN1; SMN2HSD17B10HPGDPDE8B | |
| SCHEMBL13845953 | 0.80 | CHRM2 (0.39) | SMN1; SMN2HSD17B10HPGDPDE8B | |
| SCHEMBL31320074 | 0.79 | ALOX15 (0.37) | SMN1; SMN2HSD17B10PTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066329-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-27 | — | — | US | disclosed |
| WO-2025036713-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066329-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | SMN1; SMN2 4484/4885HSD17B10 2790/4885PTPN2 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.